Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of alpha2bbeta3 integrin receptor expressed on human surface of platelets
Assay data:3 Activity ≤ 1 µM, 3 Tested
SummaryCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Affinity Assay from US Patent US9345793: "Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi"
Assay data:20 Active, 20 Activity ≤ 1 µM, 20 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Binding Assay from US Patent US8927534: "Compounds for the inhibition of integrins and use thereof"
Assay data:12 Activity ≤ 1 µM, 12 Tested
SummaryCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Enzyme Assay from US Patent US9744252: "Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi"
Binding affinity to human integrin alpha2bbeta3 incubated for 1 hr by ELISA based solid phase integrin binding assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 7 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Agonist activity at alpha2bbeta3 in human K562 cells assessed as increase in cell adhesion to fibrinogen pre-incubated for 30 mins and further incubated for 1 hr in presence of alpha2bbeta3 antagonist Tirofiban by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic assay
Assay data:3 Active, 4 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Antagonist activity at alpha2bbeta3 in human HEL cells assessed as reduction in cell adhesion to fibrinogen pre-incubated for 30 mins before fibrinogen and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic assay
Assay data:2 Active, 1 Activity ≤ 1 µM, 18 Tested
Agonist activity at alpha2bbeta3 in human HEL cells assessed as increase in cell adhesion to fibrinogen pre-incubated for 30 mins before fibrinogen and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic assay
Inhibition of fibrinogen binding to alpha2bbeta3 isolated from human HEL cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay
Assay data:2 Active, 8 Activity ≤ 1 µM, 12 Tested
Inhibition of fibrinogen binding to human platelet integrin alpha2b beta3 by ELISA based solid phase binding assay
Assay data:3 Active, 2 Activity ≤ 1 µM, 6 Tested
Inhibition of FITC-dodecapeptide binding to human integrin alpha2b beta3 receptor stably expressed in CHO Lec.3.2.8.1 cells by fluorescence anisotropy
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human fibrinogen binding to human platelet integrin alpha2b-beta3 receptor after 1 hr by solid-phase binding assay
Assay data:6 Activity ≤ 1 µM, 6 Tested
Inhibition of human fibronectin binding to human Integrin alpha2b beta3 receptor incubated for 1 hr by ELISA
Assay data:3 Active, 1 Activity ≤ 1 µM, 22 Tested
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Displacement of [3H]UR-3189 from integrin alpha2b beta3 receptor in resting human platelet
Antagonist activity at integrin alpha2b beta3 receptor in citrated human platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
Antagonist activity at integrin alpha2b beta3 receptor in citrated human platelet-rich plasma assessed as inhibition of ADP-induced platelets aggregation preincubated for 15 mins followed by ADP addition measured for 8 mins by aggregometric analysis
Assay data:1 Active, 1 Tested
Antagonist activity at integrin alpha2b beta3 receptor in human platelet-rich plasma assessed as inhibition of ADP-induced platelets aggregation by light transmittance agregometric analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human GP2b/3a interaction with human fibrinogen after 3 hrs by ELISA
Inhibition of GP2b/3a in human platelet-rich plasma assessed as reduction in collagen-induced platelet aggregation preincubated for 1 min followed by collagen addition by aggregometric analysis
Assay data:3 Active, 2 Activity ≤ 1 µM, 3 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on